A case of sensory ataxic Guillain-Barré syndrome with immunoglobulin G anti-GM1 antibodies following the first dose of mRNA COVID-19 vaccine BNT162b2 (Pfizer).

Authors	T Fukushima, M Tomita, S Ikeda, N Hattori
Journal	QJM : monthly journal of the Association of Physicians (QJM) Vol. 115 Issue 1 Pg. 25-27 (01 21 2022) ISSN: 1460-2393 [Electronic] England
PMID	34871447 (Publication Type: Case Reports, Journal Article)
Chemical References	COVID-19 Vaccines Immunoglobulin G RNA, Messenger BNT162 Vaccine
Topics	BNT162 Vaccine COVID-19 COVID-19 Vaccines Guillain-Barre Syndrome Humans Immunoglobulin G RNA, Messenger SARS-CoV-2

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!